Replicel Postpones Filing of Interim Financial Statements and MD&A Due to COVID-19 Related Delays August 28, 2020
RepliCel Life Sciences Announces Closing of Debt Settlement and Additional Debt Settlement August 19, 2020
Replicel Announces Update on Filing of Annual Financial Statements and MD&A Due to COVID-19 Related Delays July 27, 2020
RepliCel Life Sciences Announces the Closing of the First Tranche Private Placement and Amendments to Debt Settlement July 15, 2020
Replicel Announces Update on Filing of Annual and Interim Financial Statements and MD&A Due to COVID-19 Related Delays July 13, 2020
Replicel Announces Update on Filing of Annual and Interim Financial Statements and Md&A Due to Covid-19 Related Delays June 29, 2020
Replicel Postpones Filing of Annual Financial Statements and MD&A Due to COVID‐19 Related Delays April 22, 2020
Japan’s Regulatory Agency, PMDA, Clears RepliCel Life Sciences to Proceed to Final Consultation for Tendon and Skin Cell Therapy Products March 11, 2020
Japan’s Patent Office Issues RepliCel Two New Patents for its Regenerative Medicine Technologies March 10, 2020